Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Covalon TechnologiesCVALF +2.53%85 Days Sales Outstanding is 35.91 as of Mar. 2026, which is 46% below its 10-year median of 66.09. GuruFocus rates CVALF with a GF Score™ of 85/100 and a GF Value™ of $1.69 (Fairly Valued). The stock has 3 warning signs investors should review. Among 811 Medical Devices & Instruments companies, Covalon Technologies ranks better than 71.64% on this metric.
The historical rank and industry rank for Covalon Technologies's Days Sales Outstanding or its related term are showing as below:
CVALF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 22.48 Med: 66.09 Max: 111.92
Current: 49.57
During the past 13 years, Covalon Technologies's highest Days Sales Outstanding was 111.92. The lowest was 22.48. And the median was 66.09.
CVALF's Days Sales Outstanding is ranked better than 71.64% of 811
companies
in the Medical Devices & Instruments industry
Industry Median: 65.18
vs CVALF: 49.57
Covalon Technologies's Days Sales Outstanding
declined
from Mar. 2025 (61.77) to Mar. 2026 (35.91).
Covalon Technologies (OTCPK:CVALF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Covalon Technologies Days Sales Outstanding Related Terms
Covalon Technologies Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Covalon Technologies's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CVALF vs ISRG, BDX, MDLN: Days Sales Outstanding Comparison
For the Medical Instruments & Supplies subindustry, Covalon Technologies's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Covalon Technologies Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Covalon Technologies's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Covalon Technologies's Days Sales Outstanding falls into.
Covalon Technologies Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Covalon Technologies (CVALF) has a Days Sales Outstanding of 35.91 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Covalon Technologies and its competitors. This is 46% below median its historical median of 66.09. Over the past decade, Covalon Technologies' Days Sales Outstanding has ranged from 22.48 to 111.92. According to the industry distribution chart, Covalon Technologies ranks #230 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 28.4%.
Is Covalon Technologies' Days Sales Outstanding too high?
Covalon Technologies' current Days Sales Outstanding of 35.91 is 46% below median its 10-year median of 66.09. Over the past 10 years, this metric has ranged from a low of 22.48 to a high of 111.92. The Medical Devices & Instruments industry median Days Sales Outstanding is 65.18. Covalon Technologies' value of 35.91 is 44.9% below this industry median. Based on the distribution chart, Covalon Technologies ranks #230 out of 811 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Covalon Technologies has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Covalon Technologies' Days Sales Outstanding compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Covalon Technologies ranks #230 out of 811 companies for Days Sales Outstanding. This puts Covalon Technologies in the upper half of its industry. The industry median Days Sales Outstanding is 65.18. Covalon Technologies' value of 35.91 is 44.9% below this benchmark. Historically, Covalon Technologies' own Days Sales Outstanding has ranged from 22.48 to 111.92 over the past decade. While the company's 10-year median is 66.09 vs. the industry median of 65.18, Covalon Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 65.18, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Covalon Technologies's current Days Sales Outstanding of 35.91 is 44.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Covalon Technologies and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 65.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Covalon Technologies's current Days Sales Outstanding is 35.91, which is 46% below median its own 10-year median of 66.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Covalon Technologies stock overvalued right now?
Based on GuruFocus' analysis, Covalon Technologies (CVALF) is currently considered Fairly Valued. The stock's GF Value™ is $1.69, compared to a current price of $1.62 — trading 4.1% below its estimated fair value. The current Days Sales Outstanding is 35.91, which is 46% below median its 10-year median of 66.09 and 44.9% below the Medical Devices & Instruments industry median of 65.18. Covalon Technologies' overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Covalon Technologies (CVALF), the current Days Sales Outstanding is 35.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Covalon Technologies (CVALF) Overvalued in 2026?
Based on GuruFocus' analysis, Covalon Technologies stock appears to be undervalued.
The current stock price of $1.62 is trading 4.1% below its estimated GF Value™ of $1.69.
GuruFocus considers Covalon Technologies to be Fairly Valued.
Key valuation signals for CVALF:
Days Sales Outstanding: 35.91 (46% below median its 10-year median of 66.09)
GF Value™: $1.69 vs. price of $1.62 (4.1% below fair value)
Industry Position: 44.9% below the Medical Devices & Instruments median (#230 of 811)
No single metric tells the full story. See the CVALF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Covalon Technologies Ltd is engaged in the business of researching, developing, manufacturing, and marketing patent-protected medical products that improve patient outcomes in the areas of infection management, wound care, and surgical procedures. The company generates revenue through development contracts, licensing agreements, distribution contracts, and sales. Its products include IV dressings, surgical site protection products, vascular access protection products, and others, and its solutions include primary dressing cover, vascular access technologies, advanced wound care, sensitive skin solutions, custom medical coatings, and patient resource support.
85GF Score
Get the complete analysis for CVALF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVALF has been successfully added to your 
